Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 18;9(2):471.
doi: 10.3390/cells9020471.

CD38 in Neurodegeneration and Neuroinflammation

Affiliations
Review

CD38 in Neurodegeneration and Neuroinflammation

Serge Guerreiro et al. Cells. .

Abstract

Neurodegenerative diseases are characterized by neuronal degeneration as well as neuroinflammation. While CD38 is strongly expressed in brain cells including neurons, astrocytes as well as microglial cells, the role played by CD38 in neurodegeneration and neuroinflammation remains elusive. Yet, CD38 expression increases as a consequence of aging which is otherwise the primary risk associated with neurodegenerative diseases, and several experimental data demonstrated that CD38 knockout mice are protected from neurodegenerative and neuroinflammatory insults. Moreover, nicotinamide adenine dinucleotide, whose levels are tightly controlled by CD38, is a recognized and potent neuroprotective agent, and NAD supplementation was found to be beneficial against neurodegenerative diseases. The aims of this review are to summarize the physiological role played by CD38 in the brain, present the arguments indicating the involvement of CD38 in neurodegeneration and neuroinflammation, and to discuss these observations in light of CD38 complex biology.

Keywords: ALS.; Alzheimer’s disease; CD38; NAD; Parkinson’s disease; aging; neurodegeneration; neuroinflammation.

PubMed Disclaimer

Conflict of interest statement

S.G, L.B., D.T. are founders and shareholders of Encefa. A.-L.P. is employed by Encefa. Encefa is a biotechnology company developing an anti-CD38 antibody against neurodegenerative diseases.

Figures

Figure 1
Figure 1
Cartoon summarizing current data on CD38 expression and functions in neuronal and glial cells.
Figure 2
Figure 2
Hypothetic role played by CD38 in neurodegeneration and neuroinflammation. Normal or pathological aging is characterized by an increased number of senescent cells in the brain, mostly astrocytes, which adopt a senescence-associated secretory phenotype (SASP) characterized by the release of proinflammatory cytokines and chemokines. These proinflammatory factors increase CD38 expression in astrocytes and microglial cells, leading to (i) amplified release of proinflammatory cytokines and neuroinflammation as well as (ii) NAD depletion due to increased CD38 enzymatic activity that results in reduced activity of the NAD-dependent enzymes sirtuins and PARP, accumulation of DNA damage as well as metabolic dysfunctions and oxidative stress, leading to neuronal impairment and ultimately cell death.

Similar articles

Cited by

References

    1. Gan L., Cookson M.R., Petrucelli L., La Spada A.R. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat. Neurosci. 2018;21:1300–1309. doi: 10.1038/s41593-018-0237-7. - DOI - PMC - PubMed
    1. Ransohoff R.M. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777–783. doi: 10.1126/science.aag2590. - DOI - PubMed
    1. Mehta D., Jackson R., Paul G., Shi J., Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin. Investig. Drugs. 2017;26:735–739. doi: 10.1080/13543784.2017.1323868. - DOI - PMC - PubMed
    1. Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S.G., Croteau D.L., Bohr V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019;15:565–581. doi: 10.1038/s41582-019-0244-7. - DOI - PubMed
    1. Lautrup S., Sinclair D.A., Mattson M.P., Fang E.F. NAD+ in Brain Aging and Neurodegenerative Disorders. Cell Metab. 2019;30:630–655. doi: 10.1016/j.cmet.2019.09.001. - DOI - PMC - PubMed

Publication types

MeSH terms